Get the Stockscreener App
39.60
1.37%
-0.55
After Hours:
39.60
Xenon Pharmaceuticals Inc stock is traded at $39.60, with a volume of 382.59K.
It is down -1.37% in the last 24 hours and down -2.75% over the past month.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
See More
Previous Close:
$40.15
Open:
$40.08
24h Volume:
382.59K
Relative Volume:
1.01
Market Cap:
$3.02B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-14.45
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
-2.15%
1M Performance:
-2.75%
6M Performance:
-5.71%
1Y Performance:
-16.95%
1-Day Range:
$39.40
$40.50
1-Week Range:
$39.25
$41.40
52-Week Range:
$35.53
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
39.60 | 3.02B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Holdings Boosted by Jennison Associates LLC - MarketBeat
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - MarketBeat
FY2025 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst - MarketBeat
SG Americas Securities LLC Buys 5,577 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Leerink Partnrs Has Bearish Outlook for XENE FY2025 Earnings - Defense World
Xenon Pharmaceuticals CEO sells shares worth $2.21 million - MSN
Learn to Evaluate (XENE) using the Charts - Stock Traders Daily
2,569 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Avior Wealth Management LLC - Defense World
Ian Mortimer Sells 22,468 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock - MarketBeat
Wedbush Lowers Earnings Estimates for Xenon Pharmaceuticals - Defense World
Q1 EPS Estimates for Xenon Pharmaceuticals Cut by Wedbush - MarketBeat
FY2029 Earnings Forecast for XENE Issued By Wedbush - Defense World
Cantor Fitzgerald Predicts XENE FY2025 Earnings - Defense World
Cantor Fitzgerald Estimates XENE FY2025 Earnings - MarketBeat
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Epidemic Keratoconjunctivitis Market Expected to Reach Huge - openPR
Xenon Pharmaceuticals announces executive changes - MSN
Assenagon Asset Management S.A. Has $9.35 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Assenagon Asset Management S.A. Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
Xenon Pharmaceuticals Inc. Announces Cessation of Christopher Von Seggern as Chief Commercial Office - Marketscreener.com
Barclays PLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Barclays PLC Acquires 13,903 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of “Buy” from Brokerages - Defense World
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential - Seeking Alpha
XENE Crosses Above Key Moving Average Level - Nasdaq
Xenon Pharmaceuticals Inc (XENE-Q) QuotePress Release - The Globe and Mail
Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones - TipRanks
Xenon Outlines Key Corporate Milestone Opportunities for 2025 - The Manila Times
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Trading (XENE) With Integrated Risk Controls - Stock Traders Daily
Dravet Syndrome Thereapeutics Market Size, Future Consumer Behavior and Market Dynamics (2024-2034) - 100×100 Música
Xenon to Showcase Innovations at J.P. Morgan Healthcare Conference - TipRanks
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
JPMorgan Chase & Co. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
JPMorgan Chase & Co. Buys 905,129 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
hVIVO (LON:HVO) Stock Price Down 6.8% – Here’s What Happened - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Barclays PLC - MarketBeat
Barclays PLC Has $590,000 Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Buys 32,701 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):